Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home

ExpertiseUpdated on 25 February 2026

Oxeltis _ Bridge the gap between biology and chemical matter...

Christophe Parsy

Business & Strategic Development Director at Oxeltis

Montpellier, France

About

We address this by:

Seamless integration of in silico design (CADD, SBDD, LBDD, AI/ML) in partnership with Molecular Forecaster (Montreal) and Assay development/in vitro biological screening in partnership with Partex.AI Labs

Rapid hit-to-lead and lead optimization, with a track record of delivering high-quality compounds efficiently and a highly skill team of chemists (50% Ph.D., 50% M.Sc.)

Expertise in complex and enabling chemistries, supported by our hybrid SFC platform for rapid purification and scale-up (up to 25g/day) of chiral/achiral mixtures.

Oxeltis, France-based CRO specialized in medicinal and fine organic chemistry can support early small molecule drug disocvery programs to mature at Hit to Lead and Lead optimization stage.

Field

  • Biotech, Pharma and Cosmetics

Organisation

Oxeltis

SME

Montpellier, France

Similar opportunities

  • Expertise

    Computer-aided drug discovery

    • Biotech, Pharma and Cosmetics

    Elmeri Jokinen

    CEO at Aurlide Oy

    Turku, Finland

  • Expertise

    Services

    • Healthcare
    • Biotech, Pharma and Cosmetics

    Sanjee Tawde

    VP - Business Development & Sales at Partex.AI

    Frankfurt, Germany

  • Partnership

    Drug discovery partnership

    Sandra von Meier

    Head of Business Development Life Science at Terra Quantum AG

    Munich, Germany